FDA rejects Akcea rare-disease drug that uses gene-blocking technology - STAT

FDA rejects Akcea rare-disease drug that uses gene-blocking technology - STAT

FDA rejects Akcea rare-disease drug that uses gene-blocking technology

By KATE SHERIDAN @sheridan_kate

AUGUST 27, 2018

Paula Soteropoulos, CEO of Akcea Therapeutics, in Cambridge, Mass.JOSH REYNOLDS FOR THE BOSTON GLOBE